Retatrutide Side Effects: What Clinical Studies Actually Show

Overview of the Safety Data

Retatrutide has been evaluated in Phase 1 and Phase 2 clinical trials involving several hundred participants. While this represents a substantial body of early-stage data, it is important to acknowledge that the full safety profile of any investigational drug only becomes clear through larger Phase 3 trials and post-marketing surveillance. What follows is a summary of what the published clinical data show as of the available evidence.

No unexpected or novel safety signals have emerged in the clinical program to date. The adverse event profile is broadly consistent with other incretin-based therapies, with gastrointestinal effects predominating.

Gastrointestinal Effects: The Primary Concern

As with all GLP-1 receptor agonists and related multi-receptor agonists, gastrointestinal adverse events were the most frequently reported side effects in retatrutide trials. The principal GI events included:

• Nausea: The most common adverse event across dose groups, reported by approximately 16-45% of participants depending on dose. Nausea was most frequent during the initial weeks of treatment and during dose escalation periods.
• Diarrhea: Reported by approximately 10-25% of participants, with higher rates at higher doses.
• Vomiting: Occurred in roughly 8-20% of participants, again dose-dependent.
• Decreased appetite: While partly a therapeutic mechanism, reduced appetite was reported as an adverse event by some participants.
• Constipation and dyspepsia: Less frequent but present across dose groups.

The critical context is that the majority of GI adverse events were mild to moderate in severity. Most occurred during the dose-escalation phase and tended to diminish over time as participants reached their maintenance dose.

Dose-Dependent Patterns

The Phase 2 obesity trial provided clear evidence that adverse event rates increased with dose:

At the 1 mg dose, GI adverse events were relatively infrequent and the discontinuation rate due to adverse events was 0%. At the 4 mg escalating dose, GI events were more common but remained manageable for most participants. At the 8 mg and 12 mg doses, GI adverse event rates were highest, though still within the range observed for other approved incretin therapies.

This dose-response pattern in adverse events mirrors the dose-response in efficacy, which creates a clinical trade-off between maximizing therapeutic benefit and maintaining tolerability.

The Importance of Dose Escalation

One of the most informative findings from Phase 2 was the comparison between escalating and fixed-dose 4 mg groups. Participants who started at a lower dose and escalated to 4 mg experienced fewer GI adverse events and had better overall tolerability than those who began at the full 4 mg dose immediately.

This finding directly informed the dose-escalation protocols used in the Phase 3 TRIUMPH program. Gradual titration allows the gastrointestinal system to adapt to incretin receptor stimulation, reducing the intensity and frequency of nausea and other GI effects. The clinical implication is clear: starting low and titrating slowly is essential for optimizing the tolerability of retatrutide.

Discontinuation Rates

Discontinuation due to adverse events is one of the most clinically meaningful safety metrics because it reflects events severe enough to cause patients to stop treatment entirely. In the Phase 2 obesity trial:

• Placebo: ~2% discontinuation
• 1 mg: 0%
• 4 mg (escalating): ~6%
• 4 mg (fixed): ~10%
• 8 mg: ~10%
• 12 mg: ~16%

The 16% discontinuation rate at the highest dose is notable and warrants attention. For context, Phase 3 trials of semaglutide 2.4 mg reported discontinuation rates of approximately 7%, and tirzepatide Phase 3 trials reported rates of approximately 4-7% depending on dose. Whether optimized escalation protocols in Phase 3 will reduce retatrutide’s discontinuation rate remains to be determined.

Non-GI Adverse Events

Beyond gastrointestinal effects, the clinical data revealed no significant safety concerns:

• Injection site reactions were infrequent and mild, consistent with other subcutaneous peptide therapies.
• Heart rate increases were small and dose-dependent, a known class effect of GLP-1 receptor agonists.
• No clinically significant pancreatitis, thyroid, or gallbladder signals emerged, though these are monitored carefully in ongoing trials given the known class considerations for incretin-based therapies.
• Glycemic parameters improved across groups, with no clinically significant hypoglycemia in participants without diabetes.

Phase 3 TRIUMPH-4 Safety Data (December 2025)

The Phase 3 TRIUMPH-4 trial provided a substantially larger safety dataset and confirmed the dose-dependent pattern of adverse events seen in Phase 2, while also revealing new findings.

Updated GI Rates

Phase 3 GI adverse event rates at the 12 mg dose were higher than Phase 2, consistent with the larger and more diverse study population:

• Nausea: 43.2% (12 mg) — higher than the ~24% observed in Phase 2
• Diarrhea: 33.1% (12 mg) — up from ~22% in Phase 2
• Vomiting: approximately 21% (12 mg) — up from ~13% in Phase 2

These rates are broadly comparable to those seen with semaglutide 2.4 mg (Wegovy) in STEP trials and remain consistent with the incretin-based therapy class.

Dysesthesia: A New Safety Signal

TRIUMPH-4 identified dysesthesia — abnormal sensations including tingling, numbness, or burning — as a new safety signal that was not prominent in Phase 2 data. Rates were clearly dose-dependent:

• Placebo: 0.7%
• 9 mg: 8.8%
• 12 mg: 20.9%

Dysesthesia was generally mild and infrequently led to treatment discontinuation. The signal is thought to be linked to glucagon receptor activity, which distinguishes retatrutide from GLP-1-only and dual GIP/GLP-1 agonists. This is an important finding because it represents an adverse effect not seen with other incretin-based therapies and will require monitoring in ongoing trials and post-marketing surveillance.

Phase 3 Discontinuation Rates

Treatment discontinuation due to adverse events in TRIUMPH-4:

• Placebo: 4.0%
• 9 mg: 12.2%
• 12 mg: 18.2%

The 18.2% discontinuation rate at the 12 mg dose is modestly higher than the ~16% seen in Phase 2, and higher than the ~7% reported for semaglutide 2.4 mg in STEP trials and the ~4-7% for tirzepatide in SURMOUNT trials. Whether further optimization of dose escalation can improve this rate remains an open question.

What Remains to Be Determined

While TRIUMPH-4 has substantially expanded the safety database, several questions remain. The broader Phase 3 TRIUMPH program, including trials in type 2 diabetes and MASLD populations, will provide additional safety characterization across diverse patient groups. Long-term safety beyond 68 weeks, effects in special populations, and the full characterization of the dysesthesia signal all require continued study. The safety profile of retatrutide is no longer purely preliminary — Phase 3 data are now available — but it remains incomplete compared to approved therapies with years of post-marketing surveillance.